Generics triumph in anti-inflammatory patent battle


Pfizer has settled a long-running patent dispute with generics heavyweights Teva and Actavis, which will allow them to produce generic versions of Pfizer's non-steroidal anti-inflammatory drug Celebrex (celecoxib) in the US.

The deals allow Teva and Actavis to launch their generic versions of the selective COX-2 inhibitor in December 2014, or potentially earlier under certain circumstances. Both companies have filed for approval with the US Food and Drug Administration, and will jostle for ‘first to file’ priority, which under US law will grant 180 days’ exclusivity for generic versions from the successful company.

The settlement follows a prolonged back-and-forth skirmish, with a US court invalidating one of Pfizer’s patents, only for it to be reinstated on appeal. But a successful challenge from Actavis knocked it back down again. By settling the dispute, Pfizer has bought itself seven months extra exclusivity, while allowing the generics companies to enter the market 11 months earlier than they would have done had the patent stood.


Related Content

Generics giants jostle over pain drug

4 June 2014 Business

news image

Mylan and Actavis contest Teva’s generic celecoxib exclusivity

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Flowing rivers of mercury

7 January 2015 Feature

news image

Philip Ball investigates claims that the burial chamber of China’s first emperor contains rivers of shimmering mercury

Most Commented

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Undeniable: evolution and the science of creation

7 January 2015 Review

news image

Evolutionary arguments